ECP 2022 Final Programme

Tuesday, 6 Sept 59 Scientific Programme a Tuesday ECP 2022 Basel 002 15:15–15:45 Predictive biomarkers in urology Gabriella Nesi, Italy 003 15:45–16:15 Quality control in biomarker testing Ligia Craciun, Belgium 004 16:15–16:45 Round Table with all chairs and speakers OFP-12 Oral Free Paper Session 14:45–16:45 Delhi Joint Oral Free Paper Session Molecular Pathology / Haematopathology Chairs: Jean-Christophe Sabourin, France Alexandar Tzankov, Switzerland 001 14:45–14:55 The Nrf2-ARE pathway: a potential novel therapeutic target in papillary renal cancer patients Silvia Angori, Switzerland A. Banaei-Esfahani, K. Mühlbauer, A. Kahraman, V. Pietiäinen, S. Potdar, O. Kallionemi, P. Schraml, H. Moch 002 14:55–15:05 Improving the quality of cfDNA testing – results from two years of EQA Jenni Fairley, United Kingdom M. Cheetham, S. Patton, Z. Deans 003 15:05–15:15 Common pitfalls in interpreting fusion testing results highlighted by EQA Jenni Fairley, United Kingdom Z. Deans 004 15:15–15:25 The Geneva HRD test: clinical validation on 469 samples from the PAOLA-1 trial Yann Christinat, Switzerland L. Ho, S. Clément, C. Genestie, J. Sehouli, S. Cinieri, A. Gonzalez Martin, U. Denison, K. Fujiwara, I. Vergote, G. Tognon, S. Hietanen, E. Pujade-Lauraine, I. Ray- Coquard, T. Mckee 005 15:25–15:35 Clinical utility of tumour-only targeted panel sequencing in childhood tumours Yingting Mok, Singapore C. Kuick, J. Goh, N. Chia, M. Nwe, K. Chang 006 15:35–15:45 The activation of Jagged1 signaling by chemotherapeutic agents counteracts the Oxaliplatin/5Fluorouracil- mediated anti-cancer effects: a novel mechanism of drug resistance in colon cancer Maria Pelullo, Italy S. Zema, M. De Carolis, A. Villari, A. Montalti, I. Screpanti, D. Bellavia 007 15:45–15:55 Ultra-fast gene fusion assessment as a reflex testing in daily clinical practice for advanced non-small cell lung cancer patients Christophe Bontoux, France V. Hofman, S. Heeke, L. Chalabreysse, M. Barritault, P. Bringuier, T. Fenouil, N. Benzerdjeb, H. Begueret, J. Merlio, C. Caumont, N. Piton, J. Sabourin, S. Evrard, C. Syrykh, E. Long-Mira, S. Lassalle, M. Ilié, P. Hofman 008 15:55–16:05 Nuclear markers for the diagnosis of histiocytosis Irena Ungureanu, France S. Héritier, F. Cohen-Aubart, Z. Hélias- Rodzewicz, J. Donadieu, J. Haroche, J. Emile 009 16:05–16:15 Clonality analysis of Richter's transforma- tion in CLL treated with targeted therapy Irene Xie, Canada I. Rashedi, Y. Amemiya, D. Spaner, A. Seth, Z. Ghorab, R. Goswami 010 16:15–16:25 Delineating the spatial compartmentaliza- tion of human follicular B cell metabolic dynamics Maria Maddalena Perra, Switzerland A. Noto, K. Ioannidou, M. Foglierini-Perez, C. Fenwick, L. de Leval, C. Petrovas, G. Pantaleo 011 16:25–16:35 Comparison of the accuracy of cytomor- phology, flow cytometry immunophenotyp- ing and immunohistochemistry in determining diagnostic and prognostic blast percentage groups in bone marrow in myelodysplastic syndrome and acute myeloid leukemia cases Ezgi Hacihasanoglu, Turkey